ライフサイエンスコーパス: hypnotics

1 sychotics, antidepressants, anxiolytics, and hypnotics.

2 ects of neurobiological response to sedative-hypnotics.

3 re anxiety that was unresponsive to sedative hypnotics.

4 n and need for constant infusion of sedative-hypnotics.

5 easing the use of antipsychotics or sedative-hypnotics.

6 e sedation and serve as targets for sedative hypnotics.

7 the majority of clinically relevant sedative-hypnotics.

8 er flies, and is modulated by stimulants and hypnotics.

9 idely used anxiolytics, anticonvulsants, and hypnotics.

10 icidal" with each of the modern FDA-approved hypnotics.

11 enatally exposed to benzodiazepines and/or z-hypnotics.

12 and 8.8% after the crash), nonbenzodiazepine hypnotics (5.9% before the crash and 6.0% after the cras

13 of 16), antipsychotics (10 of 12), sedative-hypnotics (6 of 10), and stimulants (6 of 10).

14 most commonly dispensed medications included hypnotics, ADHD medications, anxiolytics, and selective

15 increased risk of initiating treatment with hypnotics (AHR, 1.74 [95% CI, 1.33-2.29]) and anxiolytic

16 (aHR, 2.68; 95% CI, 1.54-4.64), sedatives or hypnotics (aHR, 2.70; 95% CI, 1.40-5.19), or nonsteroida

17 10 [95% CI, 18.30-29.20]) and treatment with hypnotics (AHR, 9.08 [95% CI, 5.52-14.90]).

18 used as anxiolytics, and for short-half-life hypnotics (all zopiclone).

19 was to estimate the risk of repeated use of hypnotics among individuals with celiac disease as a pro

20 trical activity) of intact resting muscle by hypnotics, analgesia is required to prevent pain-evoked

21 of person-crashes started nonbenzodiazepine hypnotics and 1.2% stopped nonbenzodiazepine hypnotics,

22 l agents, including anaesthetics, sedatives, hypnotics and antidepressants(1-3).

23 variety of behavioral responses to sedative-hypnotics and may directly facilitate progress in human

24 icularly addressing the fields of sedatives, hypnotics and neuromuscular blockers, however, there is

25 Regional anesthesia, as well as hypnotics and opioids, promotes intraoperative muscle re

26 Despite widespread use of standard hypnotics and sedating antidepressants for chronic insom

27 duals [9.9%] vs 1119 individuals [7.7%]) and hypnotics and sedatives (1609 individuals [12.2%] vs 151

28 f anxiolytics (OR, 1.34; 95% CI, 1.12-1.60), hypnotics and sedatives (OR, 1.21; 95% CI, 1.02-1.43), o

29 isk of ALS (eg, among individuals prescribed hypnotics and sedatives 0-1 year before diagnosis: odds

30 onset but were substantial for anxiolytics, hypnotics and sedatives, and antidepressants.

31 ontrol study, prescribed use of anxiolytics, hypnotics and sedatives, or antidepressants was associat

32 familial confounding, with the exception of hypnotics and sedatives.

33 and 1.40 [95% CI, 1.30-1.50] in children for hypnotics and sedatives; RR, 1.38 [95% CI, 1.29-1.47] in

34 For the induction dose of hypnotics and the initial dose of other drugs that have

35 Benzodiazepine hypnotics and the related nonbenzodiazepine hypnotics (z

36 dosages of antidepressants, antipsychotics, hypnotics, and antidementia medications were allowed.

37 re antidepressants, antipsychotics, sedative-hypnotics, and antidepressant-antipsychotic combinations

38 tonin reuptake inhibitors, nonbenzodiazepine hypnotics, and antihistamines for more than 4 weeks was

39 tions of antihypertensives, antidepressants, hypnotics, and anxiolytics.

40 hypnotics and 1.2% stopped nonbenzodiazepine hypnotics, and drivers in 8.4% of person-crashes started

41 cluding cannabinoids, psychedelics, sedative-hypnotics, and immunotherapeutics, such as vaccines.

42 ntidepressants, antipsychotics, anxiolytics, hypnotics, and mood-stabilizers, with statins as a negat

43 nzodiazepine benzodiazepine receptor agonist hypnotics, and opioids.

44 y alcohol, marijuana or cocaine, anesthetics/hypnotics, and oral opioids.

45 ications, including antipsychotics, sedative-hypnotics, and strong anticholinergic agents.

46 owever, the prescriptions of antipsychotics, hypnotics, and the negative control outcome, statins, sh

47 antidepressants, anxiolytics, sedatives, and hypnotics, and was consistent across age groups.

48 zepines; anxiolytics, nonbenzodiazepines, or hypnotics; and drugs not prescribed for home use.

49 n for relevant medications (antidepressants, hypnotics/anxiolytics, antipsychotics) during 12 months

50 Epidemiological studies show that hypnotics are associated with an increased risk for suic

51 Further research testing or clinical use of hypnotics as OSA alternative treatments should be discou

52 Use of sedative-hypnotics before surgery is common, but its effect on po

53 This review focused on modern, FDA-approved hypnotics, beginning with the introduction of benzodiaze

54 This review focused on modern, FDA-approved hypnotics, beginning with the introduction of benzodiaze

55 of using benzodiazepines, nonbenzodiazepine hypnotics, beta-blockers, selective serotonin reuptake i

56 cern is that benzodiazepine receptor agonist hypnotics can cause parasomnias, which in rare cases may

57 , 1.87; 95% CI, 1.70-2.06), receive sedative hypnotics concurrently (40.7% vs 7.6%, adjusted RR, 5.46

58 rivation, and can be induced by conventional hypnotics, diazepam and sodium pentobarbital.

59 Hypnotics did not affect genioglossus responsiveness (hi

60 or patients in need of benzodiazepines and z-hypnotics during pregnancy; however, these findings need

61 ta, USA) and novel 'soft-drug' sedatives and hypnotics (e.g. CNS-7259X and TD-4756) as well as a nove

62 observational studies suggested that use of hypnotics for insomnia was associated with increased ris

63 its, including diverse responses to sedative-hypnotics, have been detected on distal chromosome 1 in

64 ow-dose quetiapine compared to use of Z-drug hypnotics in a nationwide, active comparator-controlled

65 icity from accentuated responses to sedative hypnotics in active cocaine-abusing subjects.

66 ation of treatment with benzodiazepines or z-hypnotics in early, mid, or late pregnancy on the childr

67 ing evidence-based guidelines for the use of hypnotics in the management of chronic insomnia.

68 the evidence for and against the claim that hypnotics increase the risk of suicide.

69 n with opioids, preoperative use of sedative-hypnotics increases the risk of adverse outcomes after c

70 s anxiolytics, anticonvulsants, and sedative/hypnotics is limited by rapid metabolism.

71 Evidence for benzodiazepine hypnotics, melatonin agonists, and antidepressants, and

72 reshold, 4 for genioglossus responsiveness), hypnotics minimally raised arousal threshold (mean diffe

73 ntipsychotics, antidepressants, anxiolytics, hypnotics, mood stabilizers, and medications for attenti

74 tween DAAs and antidepressants, anxiolytics, hypnotics, mood stabilizers, antipsychotics and treatmen

75 While current hypnotics mostly increase non-rapid eye movement sleep (

76 is a place for the use of benzodiazepines/z-hypnotics on adult mental health wards, but they are oft

77 ns, involved in the use of benzodiazepines/z-hypnotics on adult mental health wards, were conducted a

78 acilitate deprescribing of benzodiazepines/z-hypnotics on adult mental health wards.

79 Objectives: To examine the effect of common hypnotics on arousal threshold, OSA severity, and geniog

80 r barrier to deprescribing benzodiazepines/z-hypnotics on these wards.

81 Use of benzodiazepines, nonbenzodiazepine hypnotics, opioid analgesics, and other PDI medications

82 chostimulants, antidepressants, anxiolytics, hypnotics or sedatives, or antipsychotics or prescriptio

83 ents beginning treatment with benzodiazepine hypnotics or z-drugs, we compared deaths during periods

84 eone (OR 3.70, 95% CI 2.30-5.95), and use of hypnotics (OR 2.28, 95% CI 1.20-4.30).

85 Patients may use sedatives, hypnotics, or alcohol in an effort to interrupt this pro

86 tion (TV) and exposure to opioids, sedatives-hypnotics, or general anaesthetics in neonates (O-SH-GA)

87 for deprescribing (antipsychotics, sedative-hypnotics, or strong anticholinergics).

88 iscontinuing benzodiazepine receptor agonist hypnotics (particularly in older adults) and administeri

89 renatal exposure to benzodiazepines and/or z-hypnotics, regardless of timing of exposure and number o

90 ions, including antipsychotics, anxiolytics, hypnotics, sedatives, antidepressants, and psychostimula

91 tipsychotics: AOR, 4.74 [95% CI, 3.92-5.74]; hypnotics-sedatives: AOR, 3.01 [95% CI, 2.53-3.57]; and

92 tipsychotics: AOR, 6.20 [95% CI, 5.07-7.59]; hypnotics-sedatives: AOR, 4.45 [95% CI, 3.78-5.23]; anta

93 analgesics (HR, 1.22; 95% CI, 1.08 to 1.37), hypnotics/sedatives (HR, 1.21; 95% CI, 1.07 to 1.37), an

94 analgesics (HR, 1.33; 95% CI, 1.16 to 1.52), hypnotics/sedatives (HR, 1.24; 95% CI, 1.07 to 1.43), GI

95 rst-line guideline-recommended treatment, or hypnotics/sedatives improves heart- or brain-related out

96 coupled with a prescription for anxiolytics/hypnotics/sedatives, antidepressants, antipsychotics, or

97 rgeted medication classes (opioids, sedative-hypnotics, skeletal muscle relaxants, tricyclic antidepr

98 There is no association between hypnotics, such as zopiclone, and sleep outcomes, alertn

99 For sedative-hypnotics, the phrase about side effects was 8.6-fold (9

100 ) positive modulators commonly prescribed as hypnotics to treat insomnia and/or anxiety.

101 age, diagnosis status, gender, sedatives and hypnotics use, and hypertension.

102 r sleep was defined as >/=2 prescriptions of hypnotics using prospective data from the National Presc

103 Hypnotics were hypothesized as an alternative OSA treatm

104 otics, z-drugs, or low-dose trazodone, study hypnotics were not associated with mortality.

105 n which neither antidepressants nor sedative/hypnotics were prescribed.

106 hdrawal events involving opioids or sedative-hypnotics were the main safety outcome.

107 avirus disease 2019 received higher doses of hypnotics, which was associated with prolonged coma and

108 ly in elderly patients taking benzodiazepine hypnotics, who comprise a large proportion of the depend

109 99% CI, 6.77-35.31); and 2 or more sedative-hypnotics, with anxiety disorders (OR, 2.13; 99% CI, 1.4

110 hypnotics and the related nonbenzodiazepine hypnotics (z-drugs) are among the most frequently prescr

111 ften treated with nonbenzodiazepine sedative hypnotics (Z-drugs).

112 Nonbenzodiazepine hypnotics ("Z-drugs") are prescribed for insomnia but mi

113 who initiated treatment with benzodiazepine hypnotics, z-drugs, or low-dose trazodone, study hypnoti

114 from pentobarbital as well as other sedative-hypnotics (zolpidem and ethanol) versus wild-type litter